Emergent Bio gains as RSDL sale nets $75M
https://seekingalpha.com/news/4131187-emergent-bio-stock-gains-rsdl-sale-nets-75m?source=feed_sector_healthcare
Jul 31, 2024 - Emergent Biosolutions (EBS) stock gains as the comany sells RSDL skin decontamination agent to SERB Pharmaceuticals for $75M. Read more here.
0
All You Need to Know About Bio-Rad (BIO) Rating Upgrade to Buy
https://www.zacks.com/stock/news/2312215/all-you-need-to-know-about-bio-rad-bio-rating-upgrade-to-buy?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_12_zacks_rank_upgrade-2312215
Jul 30, 2024 - Bio-Rad (BIO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
0
Novartis to collaborate with Dren Bio on bispecific antibody therapies
https://seekingalpha.com/news/4127796-novartis-to-collaborate-with-dren-bio-on-bispecific-antibody-therapies?source=feed_sector_healthcare
Jul 24, 2024 - Novartis (NVS) has entered into a collaboration with Dren Bio for the discovery and development of bispecific antibody therapies for the treatment of cancer. Read more here.
0
Nuvation Bio announces updates for its ROS1 inhibitor, Taletrectinib
https://seekingalpha.com/news/4127165-nuvation-bio-announces-updates-for-its-ros1-inhibitor-taletrectinib?source=feed_sector_healthcare
Jul 23, 2024 - Nuvation Bio (NUVB) announces updates for taletrectinib program, including data presentations at key oncology conferences in 2024.
0
GRI Bio regains compliance with Nasdaq
https://seekingalpha.com/news/4122614-gri-bio-regains-compliance-with-nasdaq?source=feed_sector_healthcare
Jul 08, 2024 - GRI Bio regains compliance with Nasdaq listing standards.
0
Innovent and IASO Bio enhance collaboration for cell therapy
https://seekingalpha.com/news/4122332-innovent-and-iaso-bio-enhance-collaboration-for-cell-therapy?source=feed_sector_healthcare
Jul 05, 2024 - Innovent Biologics and IASO Biotechnology enhance strategic collaboration in cell therapy, with Innovent acquiring an 18% stake in IASO Bio.
0
DOW Announces Launch of Bio-Based NORDEL REN EPDM at DKT 2024
https://www.zacks.com/stock/news/2296865/dow-announces-launch-of-bio-based-nordel-ren-epdm-at-dkt-2024?cid=CS-ZC-FT-analyst_blog|company_news_corporate_actions-2296865
Jul 04, 2024 - NORDEL REN EPDM is set to provide a lower-carbon product by using bio leftovers from other industries as raw material, thus helping DOW customers in the rubber business.
0
PacBio (PACB) and Form Bio to Boost AAV Industry Development
https://www.zacks.com/stock/news/2295819/pacbio-pacb-and-form-bio-to-boost-aav-industry-development?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2295819
Jul 01, 2024 - PacBio (PACB) and Form Bio collaborate to form an expert AAV Working Group to introduce essential tools for AAV development and research professionals.
0
Gossamer Bio a new outperform at Oppenheimer on seralutinib for PAH
https://seekingalpha.com/news/4118608-gossamer-bio-new-outperform-oppenheimer-seralutinib-pah?source=feed_sector_healthcare
Jun 24, 2024 - Financial analyst upbeat on Gossamer Bio's seralutinib for pulmonary arterial hypertension, predicting 984% upside potential with $9 price target.
0
FDA clears IND application for Adicet Bio’s CAR T cell therapy candidate
https://seekingalpha.com/news/4118339-fda-clears-ind-application-for-adicet-bios-car-t-cell-therapy-candidate?source=feed_sector_healthcare
Jun 24, 2024 - Adicet Bio (ACET) shares rose after FDA cleared IND for ADI-270 CAR T cell therapy in renal cell carcinoma.
0